From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.
Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Dexcom G7 15 Day CGM System Cleared by FDA
The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
Massive Trump Administration Cuts to Federal Grants Halt National Diabetes Prevention Program
The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.